Výsledky vyhledávání - "Masaki Kusuda"

Pharmacological actions of anifrolumab (Saphnelo®) and clinical trial results as a treatment for systemic lupus erythematosus

Autor: Takeshi Ueha, Masaki Kusuda, Shoko Shibata, Masako Hirata, Naoko Ozaki

Publikováno v: Folia Pharmacologica Japonica. 157:271-279

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5cb7120be69601525d38445e2580cca5
https://doi.org/10.1254/fpj.22026

Zobrazit plný text záznamu

Interferons and systemic lupus erythematosus: Pathogenesis, clinical features and treatments in interferon-driven disease

Autor: Yoshiya Tanaka, Masaki Kusuda, Yoshiyuki Yamaguchi

Publikováno v: Modern rheumatology.

Type I interferons (IFNs) have recently received a lot of attention with the elucidation of the pathogenesis of systemic lupus erythematosus (SLE). Type I IFNs are associated with many SLE symptoms and play a role in the pathogenesis of autoimmune di

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::85eb09a1e071771fb3bcf8db3f78e640
https://pubmed.ncbi.nlm.nih.gov/36440704

Zobrazit plný text záznamu

Macrophage migration inhibitory factor drives pathology in a mouse model of spondyloarthritis and is associated with human disease

Publikováno v: Science translational medicine. 13(616)

Spondyloarthritis (SpA), a type 3 immunity-mediated inflammatory arthritis, is a systemic rheumatic disease that primarily affects the joints, spine, gut, skin, and eyes. Macrophage migration inhibitory factor (MIF) is a proinflammatory cytokine, yet

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dd3a0f2e8be7fe3a45a4070f0e19b4dc
https://pubmed.ncbi.nlm.nih.gov/34851696

Zobrazit plný text záznamu

Complexity of enthesitis and new bone formation in ankylosing spondylitis: current understanding of the immunopathology and therapeutic approaches

Autor: Akihiro Nakamura, Nigil Haroon, Masaki Kusuda

Publikováno v: Modern rheumatology. 32(3)

Despite increasing availability of treatments for spondyloarthritis (SpA) including tumour necrosis factor (TNF) and interleukin-17 (IL-17) inhibitors, there is no established treatment that abates new bone formation (NBF) in ankylosing spondylitis (

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6969e4946b7ba4bff9981b42c50a3e91
https://pubmed.ncbi.nlm.nih.gov/34918137

Zobrazit plný text záznamu

Akademický článek

Complexity of enthesitis and new bone formation in ankylosing spondylitis: current understanding of the immunopathology and therapeutic approaches.

Autor: Masaki Kusuda, Nigil Haroon, Akihiro Nakamura

Publikováno v: Modern Rheumatology; May2022, Vol. 32 Issue 3, p484-492, 9p

Zobrazit plný text záznamu

Right‐ventricular outflow tract obstruction by adrenocorticotrophic hormone therapy for infantile spasms after Norwood operation

Autor: Yoshifumi Kawano, Shinsuke Maruyama, Daisuke Hazeki, Kentaro Ueno, Masaki Kusuda

Publikováno v: Pediatrics International. 62:96-97

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::882c9c2aceb3888d9d4d1c5327a80526
https://doi.org/10.1111/ped.14040

Zobrazit plný text záznamu

Brentuximab Vedotin and High-dose Methotrexate Administrated Alternately for Refractory Anaplastic Large-cell Lymphoma With Central Nervous System Disease

Autor: Takuro Mitsunobu, Yasuhiro Okamoto, Shunsuke Nakagawa, Yoshifumi Kawano, Masaki Kusuda, Yuichi Kodama, Takuro Nishikawa

Publikováno v: Journal of pediatric hematology/oncology. 42(6)

Pediatric anaplastic large-cell lymphoma (ALCL), which is characterized by strong expression of CD30, is usually responsive to multidrug chemotherapy. Brentuximab vedotin (BV) which is an anti-CD30 antibody-drug conjugate is a promising drug with eff

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::40ffb4c9eafd73e2285f5d3b7210a589
https://pubmed.ncbi.nlm.nih.gov/31274669

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání